The oncolytic virus H101 combined with <i>GNAQ</i> siRNA‐mediated knockdown reduces uveal melanoma cell viability

Abstract

In summary, a therapy combining H101 and siGNAQ is feasible, with potential utility as a novel targeted molecular therapy for UM, especially those carrying a GNAQ mutation.